现代医药卫生2025，Vol.41Issue(8)：1788-1792,5.DOI:10.3969/j.issn.1009-5519.2025.08.003
PD-1单抗联合尼妥珠单抗及化疗治疗EGFR阳性复发/转移头颈部鳞癌的临床研究
Clinical study of PD-1 monoclonal antibody combined with nimotuzumab and chemotherapy in the treatment of EGFR-positive recurrent/metastatic squamous cell carcinoma of the head and neck
摘要
Abstract
Objective To explore the efficacy and safety of programmed death receptor 1(PD-1)mono-clonal antibody combined with nimotuzumab and chemotherapy in the treatment of anti-epidermal growth fac-tor receptor(EGFR)-positive recurrent/metastatic squamous cell carcinoma of the head and neck.Methods A total of 39 patients diagnosed with advanced head and neck tumors who were admitted to the Second People's Hospital of Jiangyou City from August 2022 to February 2023 were selected as the research objects and divid-ed into the observation group(20 cases)and the control group(19 cases)by the random number table meth-od.The control group was treated with chemotherapy combined with nimotuzumab,while the observation group was treated with PD-1 monoclonal antibody in addition to chemotherapy combined with nimotuzumab.The clinical remission rate,disease control rate,survival rate,and quality of life before and after treatment of the two groups of patients were compared.Results The objective response rate[85.00%(17/20)]and disease control rate[95.00%(19/20)],1-year survival rate[90.00%(18/20)vs.57.89%(11/19)]of patients in the observation group were significantly higher than those in the control group[52.63%(10/19),68.42%(13/19),57.89%(11/19),respectively].The differences were all statistically significant(P<0.05).There was no statistically significant difference in the incidence of grade Ⅲ and Ⅳ adverse reactions between the two groups of patients(P>0.05).In the observation group,patients had fatigue[30.00%(6/20)],digestive tract reac-tions[20.00%(4/20)],decreased white blood cells[25.00%(5/20)],decreased platelets[10.00%(2/20)],decreased absolute neutrophil count[25.00%(5/20)],and elevated γ-glutamyl transferase.The incidences of grade Ⅰ and Ⅱ adverse reactions such as 15.00%(3/20)were significantly lower than those in the control group[47.37%(9/19),42.11%(8/19),42.11%(8/19),36.84%(7/19),47.37%(9/19),31.58%(6/19),re-spectively].The differences were all statistically significant(P<0.05).Conclusion The treatment of EGFR-positive,recurrent/metastatic squamous cell carcinoma of the head and neck with nimotuzumab combined with PD-1 monoclonal antibody and chemotherapy can effectively improve the therapeutic effect,enhance the quali-ty of life,and thereby increase the survival rate of patients.It has high clinical application value.关键词
复发/转移头颈部鳞癌/抗表皮生长因子受体阳性/尼妥珠单抗/PD-1单抗Key words
Recurrence/metastasis squamous cell carcinoma of the head and neck/Positive for anti-epidermal growth factor receptor/Nimotuzumab/PD-1 monoclonal antibody分类
医药卫生引用本文复制引用
杨宇,李冲..PD-1单抗联合尼妥珠单抗及化疗治疗EGFR阳性复发/转移头颈部鳞癌的临床研究[J].现代医药卫生,2025,41(8):1788-1792,5.基金项目
重庆市大足区科技发展项目(DZKJ2022JSYJ-KWXM1003). （DZKJ2022JSYJ-KWXM1003）
